New hope for tough bladder cancers: immunotherapy meets chemo
NCT ID NCT03575013
Summary
This early-stage study tested whether combining an immunotherapy drug (avelumab) with a chemotherapy drug (docetaxel) is safe and effective for people with advanced bladder cancer that has spread. The trial specifically focused on patients whose cancer didn't respond to standard platinum-based chemotherapy or who couldn't receive it due to side effects. Researchers aimed to find the safest dose and see if the combination could shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.